This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    LEveraging Methylated DNA Markers in the Detection of Endometrial Cancer
Previous Study | Return to List | Next Study

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer (ECHO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05051722
Recruitment Status : Recruiting
First Posted : September 21, 2021
Last Update Posted : April 9, 2024
Sponsor:
Information provided by (Responsible Party):
Jamie N. Bakkum-Gamez, Mayo Clinic

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma.

This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in tampon-collected vaginal fluid and 2) ovarian cancer (OC) in plasma and tampon-collected vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.


Condition or disease Intervention/treatment
Endometrial Cancer Cervical Cancer Atypical Endometrial Hyperplasia Cervical Dysplasia Adnexal Mass Ovarian Cancer Diagnostic Test: Tampon Collection Diagnostic Test: Blood Collection

Detailed Description:

Detection of endometrial, ovarian, and cervical cancers at an early stage vastly increases the chances of cure and may also avert morbidity secondary to surgical staging, radiation, and/or chemotherapy. Despite the great successes of cervical cancer screening, comparable early detection methods for other gynecologic cancers and their precursors are not available. While nearly 1.5 million women per year in the United States are evaluated for abnormal uterine bleeding (AUB) or postmenopausal bleeding (PMB), the most common symptom of endometrial cancer, most undergo an invasive diagnostic biopsy with the finding of benign etiology.

Vaginal bleeding is often the only presenting symptom of women ultimately diagnosed with endometrial cancer (EC) or its precursor lesion, endometrial hyperplasia(EH). More than 90% of women with EC present with vaginal bleeding. Cervical cancer and cervical dysplasia can present as intermenstrual bleeding, post-coital bleeding, or other abnormal vaginal bleeding. However, most women who present with AUB or PMB have a benign etiology.

There are approximately 70 million women ≥45 years of age in the United States based on the most recent census data. Between 4-11% of women will be worked up for perimenopausal AUB or PMB in their lifetime. As only 5-10% of those women will have an EC or EH, there is a great clinical need for a less invasive clinical diagnostic test that can reliably distinguish between benign uterine bleeding and bleeding associated with an underlying endometrial cancer, cervical cancer, or a precursor lesion.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2640 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer: a Phase II Clinical Study
Actual Study Start Date : August 3, 2021
Estimated Primary Completion Date : June 30, 2025
Estimated Study Completion Date : December 30, 2025

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Cohort 1 - AUB / PMB
Women ≥45 years of age, presenting with abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB). These presenting symptoms clinically warrant evaluation such as an endometrial biopsy to assess for underlying endometrial cancer, endometrial hyperplasia or other endometrial pathology.
 Diagnostic Test: Tampon Collection
A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
Other Name: Vaginal Fluid

Diagnostic Test: Blood Collection
A blood sample will be collected from each participant prior to undergoing any exams or procedures.
Cohort 2 - Biopsy-proven EC or AEH or EIN
Women ≥18 years of age with biopsy-proven endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN) presenting for surgical management of their endometrial pathology.
 Diagnostic Test: Tampon Collection
A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
Other Name: Vaginal Fluid

Diagnostic Test: Blood Collection
A blood sample will be collected from each participant prior to undergoing any exams or procedures.
Cohort 3 - Cervix pathology
Women ≥18 years of age presenting for a clinically indicated colposcopy, cervical biopsy, or surgical excision, as follow-up for an abnormal Pap test or cervical mass identified on physical exam. Final clinical diagnoses within this cohort may include mild cervical intraepithelial neoplasia (CIN 1), moderate and/or severe CIN (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancers (adenocarcinoma or squamous cell carcinoma), or possibly benign findings.
 Diagnostic Test: Tampon Collection
A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
Other Name: Vaginal Fluid

Diagnostic Test: Blood Collection
A blood sample will be collected from each participant prior to undergoing any exams or procedures.
Cohort 4 - Benign Uterine Pathology
Women with any of four benign gynecologic conditions including: uterine fibroids, benign endometrial polyps, adenomyosis and endometriosis. All women enrolled in this cohort will be undergoing clinically indicated gynecologic surgery (hysterectomy, myomectomy, polypectomy, or laparoscopic tissue excision) for the specific benign gynecologic condition. Verification of the final benign diagnosis will be based on pathology diagnosis of clinically-indicated tissue removed during surgery.
 Diagnostic Test: Tampon Collection
A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
Other Name: Vaginal Fluid

Diagnostic Test: Blood Collection
A blood sample will be collected from each participant prior to undergoing any exams or procedures.
Cohort 5 - Healthy Control Women
Healthy women ≥45 years of age presenting for well-woman exams to serve as a control group. These women will have no clinically evident gynecologic precancers, gynecologic cancers, or clinically evident or symptomatic benign gynecologic conditions. These women will not have known or clinically-suspected AUB, PMB, fibroids, endometriosis, benign endometrial polyps, or adenomyosis, nor will they have any active gynecologic or non-gynecologic acute medical conditions.
 Diagnostic Test: Tampon Collection
A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
Other Name: Vaginal Fluid

Diagnostic Test: Blood Collection
A blood sample will be collected from each participant prior to undergoing any exams or procedures.
Cohort 6- Isolated Adnexal Mass Cohort (ovarian or fallopian mass)
Women ≥50 years of age and postmenopausal (12 months since LMP or available blood hormone levels confirming postmenopausal status) and an isolated adnexal mass or isolated bilateral adnexal masses being surgically removed. These patients will have a final diagnosis of any of the following: benign ovarian neoplasm, borderline tumor of the ovary, or clinically early-stage OC.
 Diagnostic Test: Tampon Collection
A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
Other Name: Vaginal Fluid

Diagnostic Test: Blood Collection
A blood sample will be collected from each participant prior to undergoing any exams or procedures.
Cohort 7 - OC Cohort - Biopsy proven or clinically suspected ovarian cancer (OC)
Women ≥18 years of age with ovarian cancer (OC) (clinically probable based on distribution of pelvic/abdominal masses on imaging, elevated CA-125, ascites, and/or imaging-guided biopsy proven) presenting for neoadjuvant chemotherapy or primary surgical management (debulking or staging) of their OC. The umbrella of OC also includes fallopian tube cancer and primary peritoneal cancer. All histologies are eligible for enrollment.
 Diagnostic Test: Tampon Collection
A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
Other Name: Vaginal Fluid

Diagnostic Test: Blood Collection
A blood sample will be collected from each participant prior to undergoing any exams or procedures.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Develop predictive models from a panel of EC-specific MDMs and validate their performance in identifying underlying EC and AEH within tampon-collected vaginal fluid in a larger, more diverse cohort. [ Time Frame: 18 months ]
    Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based endometrial cancer detection test performed on vaginal fluid collected via intravaginal tampon. The phase II aspect of this biomarker development study will narrow the number of endometrial cancer MDMs within the biomarker panel in order to optimize the next phase of test development.

  2. Develop predictive models from a panel of OC-specific MDMs and validate their performance in identifying underlying OC within tampon-collected vaginal fluid and plasma in a larger, more diverse cohort. [ Time Frame: 18 months ]
    Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based ovarian cancer detection test performed on vaginal fluid collected via intravaginal tampon. The phase II aspect of this biomarker development study will narrow the number of ovarian cancer MDMs within the biomarker panel in order to optimize the next phase of test development.


Secondary Outcome Measures :
  1. Using 95% specificity cutoffs of the final tampon-based MDM EC panel, determine the false positive rate among women undergoing surgical removal of common benign gynecologic pathology [ Time Frame: 18 months ]
    As part of this biomarker test development, understanding whether common non-cancerous uterine or gynecologic conditions may also lead to the finding of currently apparent endometrial cancer-specific MDMs in vaginal fluid is critical in determining specificity, positive predictive value, and negative predictive value of the test.


Biospecimen Retention:   Samples With DNA
  • A sample of the vaginal fluid pool will be collected via a standard tampon from each study participant prior to any clinical exams or procedures.
  • A peripheral blood sample will be collected from each study participant prior to any clinical exams or procedures.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women presenting to a GYN or GYN Surgery Clinic for evaluation of symptoms or for consultation and planned procedures as outlined in the seven study cohort descriptions.
Criteria

Inclusion Criteria for Cohort 1:

Women will be ≥45 years of age and meet at least one of the following criteria:

  • Abnormal uterine bleeding
  • Postmenopausal bleeding

Exclusion Criteria for Cohort 1:

  • Prior hysterectomy
  • Current known pregnancy diagnosis
  • Any prior pelvic or vaginal radiotherapy
  • Any prior cancer (except basal cell skin cancer) within the past 5 years
  • Chemotherapy within the past 5 years
  • Current biopsy-proven cervical, vaginal, or vulvar cancer or lower genital tract dysplasia
  • Current biopsy-proven endometrial cancer or endometrial hyperplasia - -
  • Current biopsy-proven benign endometrial polyp
  • Endometrial biopsy/sampling within the preceding 1 month showing benign endometrium

Inclusion Criteria for Cohort 2:

Women will be ≥18 years of age and meet at least one of the following criteria:

  • Presence of biopsy-proven EC (any histology, including uterine carcinosarcoma) and surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection
  • Biopsy showing AEH or EIN with surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection, etc)

Exclusion Criteria for Cohort 2:

  • Undergoing surgical procedure for recurrent or metastatic EC
  • Receipt of preoperative neoadjuvant chemotherapy or radiotherapy for current EC diagnosis
  • Prior hysterectomy
  • Current known pregnancy diagnosis
  • Prior or current biopsy-proven cervical cancer
  • Presence of concomitant biopsy-proven cervical dysplasia
  • Any prior pelvic or vaginal radiotherapy
  • Any prior cancer (except basal cell skin cancer) within the past 5 years
  • Chemotherapy within the past 5 years
  • Prior intervention or surgery with intent to completely remove the target pathology

Inclusion Criteria for Cohort 3:

Women will be ≥18 years of age, have a cervix and meet at least one of the following criteria:

  • History of current abnormal cervical/endocervical Pap test for which the patient is presenting for colposcopy
  • Cervical mass identified on physical exam and patient referred for cervical biopsy, even if colposcopy not recommended or indicated
  • Planned clinically indicated surgical excisional biopsy or removal of the cervix (cold knife cone, LEEP, hysterectomy) for abnormal Pap test, cervical dysplasia, cervical mass, or biopsy-proven invasive cervical cancer (adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or less common primary cervical carcinomas all eligible)

Exclusion Criteria for Cohort 3:

  • History of pelvic or vaginal radiotherapy
  • Prior total hysterectomy (cervix removed) for any indication
  • Current known pregnancy diagnosis
  • Cervical mass biopsy-proven to be EC or a cancer metastatic from a non-cervical origin
  • Any prior cancer (except basal cell skin cancer) within the past 5 years
  • Chemotherapy within the past 5 years
  • Patients presenting for colposcopy as part of lower genital tract dysplasia or cancer surveillance after prior curative intent treatment and no current Pap abnormality or cervical mass
  • Prior intervention or surgery with intent to completely remove the target pathology

Inclusion Criteria for Cohort 4:

Women will be ≥45 years of age and should meet at least one of the following criteria:

  • Undergoing hysterectomy with biopsy-proven or clinically presumed (based on imaging and/or clinical symptoms) benign gynecologic or uterine pathology of fibroids, endometriosis, adenomyosis, or benign endometrial polyps.
  • Undergoing any gynecologic surgery in which a benign pathologic tissue diagnosis of fibroids, endometriosis, adenomyosis, or benign endometrial polyp is anticipated to be confirmed.

Exclusion Criteria for Cohort 4:

  • Endometrial biopsy or office hysteroscopy within 2 weeks preceding the planned gynecologic surgery procedure for fibroids, endometriosis, benign endometrial polyps, or adenomyosis
  • Any surgery within the past 3 months
  • Prior hysterectomy
  • Current known pregnancy diagnosis
  • Prior or current biopsy-proven gynecologic cancer
  • Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia
  • Prior pelvic or vaginal radiotherapy
  • Any prior cancer (except basal cell skin cancer) within the past 5 years
  • Chemotherapy within the past 5 years
  • Undergoing hysterectomy for prolapse without a coexisting known or presumed benign uterine pathologic diagnosis of fibroids, endometriosis, benign endometrial polyps, or adenomyosis
  • Prior intervention or surgery with intent to completely remove the target pathology

Inclusion Criteria for Cohort 5:

Women will be ≥45 years of age and should meet the following criteria:

  • Presenting for well-woman exam, ± Pap test
  • No change in medical conditions, new diagnoses, or new medications within the past 6 months;

Exclusion Criteria for Cohort 5:

  • Pap test or cervical biopsy within the past 1 month
  • Endometrial biopsy or office hysteroscopy within the past 1 month
  • Any surgery within the past 3 months
  • Prior hysterectomy
  • Current known pregnancy diagnosis
  • Prior or current biopsy-proven gynecologic cancer
  • Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia
  • Prior pelvic or vaginal radiotherapy
  • Any prior cancer (except basal cell skin cancer) within the past 5 years
  • Chemotherapy within the past 5 years
  • Criteria met for inclusion in any of the other study cohorts

Inclusion Criteria for Cohort 6:

Women ≥50 years of age and:

  • Postmenopausal status
  • At least 1 intact ovary
  • Diagnosis of an adnexal mass or a clinical suspicion of early-stage ovarian cancer (including fallopian tube cancer)
  • Planned surgery for the adnexal mass
  • For tampon collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion)

Exclusion criteria - Isolated Adnexal Mass cohort: (Cohort 6)

  • Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn)
  • Chemotherapy for cancer treatment within the past 5 years prior to collection
  • Clinically-suspected advanced stage ovarian cancer (Stage III or IV) on presentation, if known prior to specimen collection
  • Surgical candidates for recurrent ovarian cancer
  • History of pelvic or vaginal radiation therapy
  • Known current synchronous endometrial cancer or hyperplasia
  • Known current cervical, vaginal, or vulvar dysplasia

Inclusion criteria - OC Cohort: (Cohort 7)

Women will be ≥18 years of age and meet the following criteria:

  • Presence of clinically probable ovarian, fallopian tube, or primary peritoneal cancer (all under the umbrella of OC) based on clinical findings of any/all of the following: imaging showing adnexal and/or abdominal masses consistent with probable ovarian cancer, omental caking, elevated CA125, ascites, imaging-guided biopsy consistent with OC pathology
  • Newly diagnosed with ovarian, fallopian tube or primary peritoneal cancer without neoadjuvant therapy
  • At least one intact ovary
  • For tampon collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion)

Exclusion criteria - OC Cohort (Cohort 7):

  • Patients with recurrent OC
  • Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn) within the past 5 years
  • Chemotherapy for cancer treatment within the past 5 years prior to collection
  • History of pelvic or vaginal radiation therapy
  • Known current synchronous endometrial cancer or hyperplasia
  • Known current cervical, vaginal, or vulvar dysplasia
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05051722


Contacts
Layout table for location contacts
Contact: Maureen A Lemens, BSN 507-293-1487 lemens.maureen@mayo.edu
Contact: Clinical Trials Referral Office 855-776-0015 mayocliniccancerstudies@mayo.edu

Locations
Layout table for location information
United States, Florida
Mayo Clinic Recruiting
Jacksonville, Florida, United States, 32224
Contact: Jessica Hoag, CRC       hoag.jessica@mayo.edu   
Contact: Kaylee F. Hoffman, CRC       hoffman.kaylee@mayo.edu   
Principal Investigator: Christopher C DeStephano, M.D., MPH         
My GYN Care Recruiting
Miami, Florida, United States, 33156
Contact: Raelan Santos, CRC    561-614-6080    Raelan.Santos@elligodirect.com   
Contact: Nancy Slay, CRC       Nancy.Slay@elligodirect.com   
Principal Investigator: Joyce R. Miller, M.D.         
Sub-Investigator: Karen V. Seetal Kihei, ARNP-BC         
Genoma Research, Inc. Recruiting
Miami, Florida, United States, 33173
Contact: Laura Lucia, BHSc, CRC    305-392-1264    lauralucia@genoma.comcastbiz.net   
Principal Investigator: Guillermo Lievano, D.O.         
Sub-Investigator: Itsel Cardenas, PhD, APRN         
Signature Women's Healthcare, LLC Recruiting
Pembroke Pines, Florida, United States, 33029
Contact: Raelan Santos, CRC    954-447-1446    Raelan.Santos@elligodirect.com   
Contact: Nancy Slay, CRC       Nancy.Slay@elligodirect.com   
Principal Investigator: Pablo E Uribasterra, M.D.         
Sarasota Memorial Health Care System Recruiting
Sarasota, Florida, United States, 34239
Contact: Rachael Sanacore       Rachael-Sanacore@smh.com   
Contact: Megan Swiger       Megan-Swiger@smh.com   
Principal Investigator: Toni P Kilts, D.O.         
Sub-Investigator: Beverly J Long, M.D.         
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Katrina Cabrera    773-834-6413    kcabrera1@bsd.uchicago.edu   
Contact: Veronika Sesari       vseseri@bsd.uchicago.edu   
Principal Investigator: Kathryn Mills, M.D.         
Providea Health Partners, LLC Recruiting
Evergreen Park, Illinois, United States, 60805
Contact: Annette Briseno, M.A., CRC    708-571-2901    annette.briseno@elligodirect.com   
Principal Investigator: Kenneth Finkelstein, D.O.         
Sub-Investigator: Tanya West-Hutchins, MSN, FNP-BC         
United States, Michigan
Valley OB-GYN Clinic Recruiting
Saginaw, Michigan, United States, 48602
Contact: Mackenzie Rittenberg, CCRC    989-899-7263    mackenzie.rittenberg@elligodirect.com   
Contact: Jacqueline Lang, CCRC    989-272-9065    jacqueline.lang@elligodirect.com   
Principal Investigator: Olivia A. Phifer-Combs, M.D.         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Maureen A Lemens, BSN    507-293-1487    lemens.maureen@mayo.edu   
Principal Investigator: Jamie N Bakkum-Gamez, MD         
United States, New York
The Woman's Health Pavilion Recruiting
Howard Beach, New York, United States, 11414
Contact: Monica Martinez, CRC    718-843-6300    mmartinez@ilovemygyn.com   
Principal Investigator: Andre H Saad, M.D.         
United States, North Dakota
Altru Health System Recruiting
Grand Forks, North Dakota, United States, 58206
Contact: Lorina Weymier       lweymier@altru.org   
Contact: Tina Schmitz, BSN    701-780-1845    tkschmitz@altru.org   
Principal Investigator: Collette Lessard, M.D.         
United States, Texas
Medical Colleagues of Texas, LLP Recruiting
Katy, Texas, United States, 77450
Contact: Huma Zafar    281-768-4943    Huma.Zafar@elligodirect.com   
Principal Investigator: Kelly A McCullagh, M.D.         
Sponsors and Collaborators
Mayo Clinic
Investigators
Layout table for investigator information
Principal Investigator: Jamie N Bakkum-Gamez, M.D. Mayo Clinic
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Jamie N. Bakkum-Gamez, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT05051722    
Other Study ID Numbers: 20-012833
NCI-2022-10826 ( Registry Identifier: NCI )
First Posted: September 21, 2021    Key Record Dates
Last Update Posted: April 9, 2024
Last Verified: April 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Uterine Cervical Neoplasms
Endometrial Neoplasms
Endometrial Hyperplasia
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Uterine Neoplasms
Carcinoma, Ovarian Epithelial
Uterine Cervical Dysplasia
Hyperplasia
 Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Genital Diseases
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Uterine Cervical Diseases
Uterine Diseases
Pathologic Processes
Precancerous Conditions